ArticleScientific reports2018
Bacteriophages are more virulent to bacteria with human cells than they are in bacterial culture; insights from HT-29 cells.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed.
- Genomic and Phenotypic Characterization of Two Novel Enterobacter Phages With EDTA-Enhanced Antibiofilm Activity.MicrobiologyOpen · 2026Article
- Regenerative Microbiology: Harnessing Bacterial Antagonism and Spatiotemporal Signaling for Diabetic Wound Repair.Smart medicine · 2026Review
- Efficacy of phage vB_EcoP_ZCEC16 in controlling Escherichia coli contamination in fresh poultry meat.BMC microbiology · 2026Article
- Isolation and characterisation of a novel Stenotrophomonas maltophilia phage vB_SmaS_BCU-1 with evaluation of mammalian cell safety.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Bacteriophage-mediated reduction of uropathogenicInfection and immunity · 2026Article
- Large-genome phage vB_Eco_ZCEC15 targets gastrointestinal MDR E. coli: evidence from in vitro and Caco-2 cell models.BMC microbiology · 2026Article
- Isolation, characterisation and potential applications of a novel bacteriophage targeting beta-lactam-resistant Staphylococcus saprophyticus.Scientific reports · 2026Article
- Prophylactic and therapeutic efficacy of Acinetobacter phage RM_A1 against carbapenem-resistant Acinetobacter baumannii with no cytotoxicity to human skin cells.BMC microbiology · 2026Article
- Addition of lactoferrin increases efficacy of three Kayviruses and limits the inflammatory response in pulmonary epithelial cells.Applied microbiology and biotechnology · 2026Article
- Phage therapy againstFrontiers in microbiology · 2026Review
- Bacteriophage-mediated reduction of uropathogenicbioRxiv : the preprint server for biology · 2025Article
- Isolation and characterization of phages ΦZC2 and ΦZC3 against carbapenem-resistant Acinetobacter baumannii, and efficacy of ΦZC3 on A549 cells.Virology journal · 2025Article
- Inflammation, toxicity, and apoptosis reducing potential of bacteriophage Ariobarzanes on intestinal cells infected with Salmonella Typhimurium.Scientific reports · 2025Article
- Efficacy of Three Kayviruses AgainstAntibiotics (Basel, Switzerland) · 2025Article
- What, how, and why? - anti-EHEC phages and their application potential in medicine and food industry.Journal of applied genetics · 2025Review
- Mucosal-adapted bacteriophages as a preventive strategy for a lethal Pseudomonas aeruginosa challenge in mice.Communications biology · 2025Article
- Phage therapy for intestinal infections: efficacy, challenges, and future directions in translational research.Frontiers in microbiology · 2025Review
- Antibacterial activity and impact on keratinocyte cell growth ofCurrent research in microbial sciences · 2025Article
- Bacteriophage entrapment strategies for the treatment of chronic wound infections: a comprehensive review.Archives of microbiology · 2024Review
- Characterization and Genomic Analyses of dsDNA Vibriophage vB_VpaM_XM1, Representing a New Viral Family.Marine drugs · 2024Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Bacteriophage therapeutic development will clearly benefit from understanding the fundamental dynamics of in vivo phage-bacteria interactions. Such information can inform animal and human trials, and much can be ascertained from human cell-line work. We have developed a human cell-based system using Clostridium difficile, a pernicious hospital pathogen with limited treatment options, and the phage phiCDHS1 that effectively kills this bacterium in liquid culture. The human colon tumorigenic cell line HT-29 was used because it simulates the colon environment where C. difficile infection occurs. Studies on the dynamics of phage-bacteria interactions revealed novel facets of phage biology, showing that phage can reduce C. difficile numbers more effectively in the presence of HT-29 cells than in vitro. Both planktonic and adhered Clostridial cell numbers were successfully reduced. We hypothesise and demonstrate that this observation is due to strong phage adsorption to the HT-29 cells, which likely promotes phage-bacteria interactions. The data also showed that the phage phiCDHS1 was not toxic to HT-29 cells, and phage-mediated bacterial lysis did not cause toxin release and cytotoxic effects. The use of human cell lines to understand phage-bacterial dynamics offers valuable insights into phage biology in vivo, and can provide informative data for human trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.